The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and the pneumococcal vaccine was unknown. We compare the immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine with that of separate administration.

162 Participants are randomly assigned to one of the two study groups; Simultaneous administration group: receive injections of pneumococcal vaccine and influenza vaccine simultaneously.

Sequential administration group: receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.

We compare the immunogenicity of the two groups.

Results

Human Vaccines and immunotherapeutics published the results of this trial on May 14, 2018.

Simultaneous administration of PPSV23 and QIV showed an acceptable immune response that was comparable to that of sequential administration without an increase in adverse reactions. Simultaneous administration of the 2 vaccines may be a promising strategy to increase PPSV23 coverage rates.